Shabir Madhi to Palivizumab
This is a "connection" page, showing publications Shabir Madhi has written about Palivizumab.
Connection Strength
0,780
-
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY). Vaccine. 2024 Oct 24; 42(24):126276.
Score: 0,238
-
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date. Paediatr Drugs. 2024 Mar; 26(2):101-112.
Score: 0,225
-
The bronchiolitis season is upon us--recommendations for the management and prevention of acute viral bronchiolitis. S Afr Med J. 2015 Sep 21; 105(7):525-6.
Score: 0,128
-
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. N Engl J Med. 2023 04 20; 388(16):1533-1534.
Score: 0,054
-
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023 03; 7(3):180-189.
Score: 0,053
-
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. N Engl J Med. 2022 03 03; 386(9):892-894.
Score: 0,050
-
Acute viral bronchiolitis in South Africa: Strategies for management and prevention. S Afr Med J. 2016 Apr; 106(4):27-9.
Score: 0,033